Literature DB >> 25714661

The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study.

Bao-Chi Chang1, Shyh-Jen Wang.   

Abstract

US common law recites a natural law, natural phenomenon or abstract idea as exceptions to the 4 statutory patentable categories to guard against the wholesale preemption of fundamental principles. The very recent evolutions of patent exceptions in the US may increase the difficulty of patenting and may create uncertainty in determining patent eligibility. To solve the thorny problem of eligibility, this study presents a flow chart based on the courts' decisions that can serve as a set of guidelines for determining patent eligibility. A case related to prostate cancer immune therapy is presented for discussion.

Entities:  

Keywords:  abstract idea; eligibility; flow chart; natural phenomenon; patent

Mesh:

Year:  2015        PMID: 25714661      PMCID: PMC4514406          DOI: 10.1080/21645515.2015.1009344

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  5 in total

1.  The European BRCA patent oppositions and appeals: coloring inside the lines.

Authors:  Gert Matthijs; Isabelle Huys; Geertrui Van Overwalle; Dominique Stoppa-Lyonnet
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

2.  Myriad decision aftershocks ripple through biotech.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

3.  Designing around patents: a guideline.

Authors:  Shyh-Jen Wang
Journal:  Nat Biotechnol       Date:  2008-05       Impact factor: 54.908

4.  Sipuleucel-T and immunotherapy in the treatment of prostate cancer.

Authors:  Nancy A Dawson; Erin E Roesch
Journal:  Expert Opin Biol Ther       Date:  2014-03-12       Impact factor: 4.388

Review 5.  Prostate cancer vaccines in combination with additional treatment modalities.

Authors:  Matthew A Uhlman; Megan T Bing; David M Lubaroff
Journal:  Immunol Res       Date:  2014-08       Impact factor: 4.505

  5 in total
  3 in total

1.  Drafting eligible biotech and immunotherapy claims.

Authors:  Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

2.  The limited benefit of "product-by-process" claim.

Authors:  Bao-Chi Chang; Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 3.  The Translation and Commercialisation of Biomarkers for Cardiovascular Disease-A Review.

Authors:  Soloman Saleh; Jacob George; Katharine A Kott; Peter J Meikle; Gemma A Figtree
Journal:  Front Cardiovasc Med       Date:  2022-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.